Lisata Therapeutics, Inc. (NASDAQ:LSTA) Short Interest Update

Lisata Therapeutics, Inc. (NASDAQ:LSTA) was the target of a large decrease in short interest in December. As of December 31st, there was short interest totaling 9,326 shares, a decrease of 39.6% from the December 15th total of 15,440 shares. Based on an average daily volume of 33,508 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.1% of the shares of the company are short sold. Approximately 0.1% of the shares of the company are short sold. Based on an average daily volume of 33,508 shares, the days-to-cover ratio is presently 0.3 days.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lisata Therapeutics in a research note on Wednesday, October 8th. Zacks Research lowered Lisata Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 10th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Lisata Therapeutics currently has a consensus rating of “Hold” and an average target price of $23.50.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of LSTA. Cerity Partners LLC purchased a new stake in Lisata Therapeutics in the 2nd quarter worth approximately $32,000. CIBC Bancorp USA Inc. purchased a new position in shares of Lisata Therapeutics during the 3rd quarter valued at approximately $37,000. Finally, Ground Swell Capital LLC acquired a new position in shares of Lisata Therapeutics in the 3rd quarter valued at $62,000. 8.94% of the stock is currently owned by hedge funds and other institutional investors.

Lisata Therapeutics Stock Performance

Shares of Lisata Therapeutics stock traded down $0.02 during trading on Friday, hitting $2.16. 34,994 shares of the company’s stock were exchanged, compared to its average volume of 38,698. The business has a 50-day simple moving average of $2.03 and a 200-day simple moving average of $2.33. Lisata Therapeutics has a 52-week low of $1.81 and a 52-week high of $4.11. The stock has a market capitalization of $19.05 million, a price-to-earnings ratio of -1.01 and a beta of 1.11.

Lisata Therapeutics (NASDAQ:LSTA) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.05. On average, equities analysts anticipate that Lisata Therapeutics will post -2.66 earnings per share for the current fiscal year.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.